The Trump administration approved a partnership with Kodak to produce critical pharmaceutical ingredients in the United States.
“America is dangerously dependent on foreign supply chains for all three stages of drug production: starting materials used to manufacture active ingredients, the active ingredients themselves and the finished product in the form of tablets, pills and injectables,” New York Post writers Peter Navarro and Adam Boehler report. Adding, “The Kodak project is a big win for the Defense Production Act, a big win for New York and the nation—and a huge step forward toward U.S. pharmaceutical independence.”
Defense Production Act
On Tuesday, President Trump announced a $765 million U.S. government loan to Kodak under the Defense Production Act (DPA). DPA, a 1950 law, gives the government authority during emergencies to direct industrial production.
The Food and Drug Administration estimates that at least 80 percent of the active ingredients found in America’s medicines come from abroad – primarily China.
“Imagine if China turned off that spigot,” says Rosemary Gibson, author of China R.X.: The Risks of America’s Dependence on China for Medicine tells Fox News in 2019.
“China’s aim is to become the global pharmacy to the world — it says that. It wants to disrupt, to dominate, and displace American and other Western companies.”
The author adds China has a complete chokehold over the United States and its supply of medicine.
“We will lose control over how much we pay. We will be the price taker, not the price setter. And that’s devastating.”
The Kodak project will aid the United States from depending on foreign supplies of quintessential pharmaceuticals.
The president signed an executive order on May 14 that designated the DPA’s authority to the “DFC’s chief executive officer to invest in the domestic production of strategic pandemic-response resources.”